Summit Therapeutics to Participate in February Investor Conferences

OXFORD, United Kingdom, Feb. 02, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that company management will participate in three upcoming investor conferences taking place in New York City in February.

• Canaccord Genuity Rare Disease and BioPharma One-on-One Day – February 7, 2017
• BIO CEO & Investor Conference – February 13, 2017; presentation at 10:30am EST
• SunTrust Robinson Humphrey Orphan Drug Day – February 14, 2017

For the Canaccord Genuity and SunTrust Robinson Humphrey events, the Company will participate in one on one meetings. A live audio webcast of the BIO CEO & Investor Conference presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

-END-